It has been a great pleasure to present our work from Cajal at Alzheimer's / Parkinson's disease conference AD/PD 2022. It was the first live conference after 2 years of covid, so the majority of people were wearing masks. The meeting was extremely well organized with speakers coming from so many different backgrounds. There were healthcare professionals, medical doctors, academic researchers and pharma partners including Biogen, Novo Nordisk, Eli Lilly and many others. There were so many insightful and deep discussions about the fundamental mechanisms of neurodegeneration, therapeutic strategies and in vivo and in vitro model systems. Our work about trajectory inference of snRNA-seq data and Transcriptome-wide association studies got a lot of attention and was well integrated into the conference. I hope to bring these insights into Cajal to improve our search to find better treatments for patients with neurodegenerative disease.